Linked Life Data

15268665

Source:http://linkedlifedata.com/resource/pubmed/id/15268665

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2004-7-22
pubmed:abstractText
Indolent non-Hodgkin's lymphomas (NHLs) comprise 35-40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90Yttrium-ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67-80%, with a median remission duration of approximately 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium-ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1744-7682
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1323-31
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
pubmed:affiliation
The Ohio State University, Division of Hematology & Oncology, Arthur G. James Cancer Hospital, Columbus 43210-1240,, USA. blum-2@medctr.osu.edu
pubmed:publicationType
Journal Article, Review